The Prostate Cancer Centre (PCC) in Calgary is proud to be a key partner in the clinical utility study of Nanostics’ ClarityDX Prostate test, an innovative AI-powered blood test designed to enhance the accuracy of prostate cancer detection. This collaboration underscores PCC’s commitment to advancing prostate cancer diagnostics and improving patient outcomes.
Advancing Prostate Cancer Diagnostics
The ClarityDX Prostate test represents a significant advancement in prostate cancer screening. Utilizing machine learning algorithms, the test analyzes a combination of biological and clinical biomarkers to generate a risk score for aggressive prostate cancer. This approach aims to improve decision-making for men with elevated prostate-specific antigen (PSA) levels, potentially reducing unnecessary biopsies and associated complications.
PCC’s Role in the Clinical Study
As a leading institution dedicated to prostate health, the PCC is actively involved in the clinical validation of the ClarityDX Prostate test. The study, which began in Alberta, includes patient recruitment and data collection facilitated by PCC’s experienced medical team. Dr. Eric Hyndman, a urologist at the PCC, serves as one of the principal investigators, bringing valuable expertise to the research initiative.
Impact on Patient Care
Preliminary data from the study indicate that the ClarityDX Prostate test offers three times the specificity of the traditional PSA test in detecting clinically significant prostate cancer. By more accurately identifying patients who require further diagnostic procedures, the test has the potential to reduce unnecessary biopsies by up to 35%, thereby minimizing patient discomfort and healthcare costs.
Collaborative Efforts and Future Outlook
This study is a collaborative effort involving Nanostics, the PCC, the Alberta Prostate Cancer Research Initiative (APCaRI), and other healthcare institutions. The collective goal is to validate the efficacy of the ClarityDX Prostate test and integrate it into standard clinical practice, ultimately enhancing the quality of care for men at risk of prostate cancer.
PCC remains committed to supporting innovative research and adopting cutting-edge technologies that benefit patients. The partnership in this clinical study exemplifies PCC’s dedication to improving prostate cancer diagnostics and outcomes through collaborative efforts and scientific advancement.
For more information about the ClarityDX Prostate test and the ongoing clinical study, read more.